Premium Nahrungsergänzungsmittel | artgerecht

Carfilzomib: Uses, Mechanism & Side Effects

Carfilzomib is a proteasome inhibitor used to treat relapsed or refractory multiple myeloma. It selectively blocks enzyme complexes in cancer cells, triggering their programmed death.

Regular tips about health Regular tips about health

Things worth knowing about "Carfilzomib"

Carfilzomib is a proteasome inhibitor used to treat relapsed or refractory multiple myeloma. It selectively blocks enzyme complexes in cancer cells, triggering their programmed death.

What is Carfilzomib?

Carfilzomib is a second-generation proteasome inhibitor used in the treatment of multiple myeloma, a malignant cancer of the plasma cells in the bone marrow. It is marketed under the brand name Kyprolis and has been approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for specific indications in patients with multiple myeloma.

Mechanism of Action

Carfilzomib works by selectively and irreversibly binding to the 20S proteasome, a key enzyme complex found in all human cells. The proteasome is responsible for breaking down damaged or unnecessary proteins. By blocking this degradation pathway, carfilzomib causes an accumulation of misfolded and damaged proteins inside tumour cells. This triggers apoptosis (programmed cell death) and inhibits the proliferation of malignant cells.

Compared to bortezomib, a first-generation proteasome inhibitor, carfilzomib acts more irreversibly and has a distinct side effect profile, particularly a lower risk of peripheral neuropathy (nerve damage in the hands and feet).

Indications

Carfilzomib is approved for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. It is typically administered in combination with other agents, such as:

Carfilzomib + Lenalidomide + Dexamethasone (KRd regimen)
Carfilzomib + Dexamethasone (Kd regimen)
Carfilzomib + Daratumumab + Dexamethasone (KDd regimen)

Dosage and Administration

Carfilzomib is administered as an intravenous (IV) infusion, meaning it is delivered directly into a vein. Treatment is given in cycles, with the exact schedule (dose, frequency, duration) determined by the treating haematologist or oncologist. A typical schedule involves infusions on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Pre-medications such as dexamethasone and adequate hydration are usually given before infusions to help reduce the risk of side effects.

Side Effects

Like all cancer medications, carfilzomib can cause side effects, which may vary in severity depending on the individual and the combination regimen used.

Common Side Effects

Fatigue and weakness
Nausea and vomiting
Anaemia (low red blood cell count)
Thrombocytopenia (low platelet count)
Shortness of breath (dyspnoea)
Fever

Serious Side Effects

Cardiac complications: Carfilzomib can cause heart failure, high blood pressure, or cardiac arrhythmias. Regular cardiac monitoring is required during treatment.
Pulmonary embolism and thrombosis: An increased risk of blood clots exists, especially in combination regimens.
Renal impairment: Kidney function must be monitored throughout treatment.
Infusion reactions: Symptoms such as fever, chills, or dizziness may occur during or shortly after the infusion.

Contraindications and Precautions

Carfilzomib should not be used in patients with known hypersensitivity to the active substance. Special caution is required in patients with:

Pre-existing heart disease
Impaired kidney function
Impaired liver function
Pregnancy or breastfeeding (carfilzomib is contraindicated in these situations)

Regular monitoring of blood counts and organ function is essential throughout the course of therapy.

References

European Medicines Agency (EMA): Kyprolis (carfilzomib) - Summary of Product Characteristics and European Public Assessment Report (EPAR). Available at: www.ema.europa.eu
Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology. 2016;17(1):27-38.
Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine. 2015;372(2):142-152.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.